Research Analysts Set Expectations for AGIO FY2027 Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Zacks Research issued their FY2027 earnings per share (EPS) estimates for Agios Pharmaceuticals in a research note issued on Thursday, March 6th. Zacks Research analyst A. Chakraborty forecasts that the biopharmaceutical company will post earnings of ($3.85) per share for the year. The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.85) per share.

AGIO has been the topic of a number of other research reports. Royal Bank of Canada raised their price target on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. Scotiabank upped their price target on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research note on Monday, December 9th. StockNews.com cut shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 14th. Finally, HC Wainwright began coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They set a “buy” rating and a $58.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $56.57.

Agios Pharmaceuticals Trading Down 4.7 %

Shares of Agios Pharmaceuticals stock opened at $32.38 on Friday. The company has a fifty day simple moving average of $33.82 and a 200-day simple moving average of $42.42. The stock has a market cap of $1.86 billion, a price-to-earnings ratio of 2.86 and a beta of 0.88. Agios Pharmaceuticals has a 12-month low of $27.14 and a 12-month high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%.

Institutional Trading of Agios Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. GF Fund Management CO. LTD. purchased a new stake in Agios Pharmaceuticals during the fourth quarter valued at about $39,000. Frazier Life Sciences Management L.P. lifted its stake in shares of Agios Pharmaceuticals by 2.5% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 1,069,754 shares of the biopharmaceutical company’s stock valued at $35,152,000 after purchasing an additional 25,600 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Agios Pharmaceuticals by 8.5% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 122,835 shares of the biopharmaceutical company’s stock worth $4,036,000 after purchasing an additional 9,606 shares during the period. Voloridge Investment Management LLC increased its position in Agios Pharmaceuticals by 2.1% during the 4th quarter. Voloridge Investment Management LLC now owns 200,481 shares of the biopharmaceutical company’s stock worth $6,588,000 after purchasing an additional 4,082 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new position in Agios Pharmaceuticals in the fourth quarter valued at approximately $5,337,000.

Insider Buying and Selling at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction on Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the transaction, the insider now owns 18,906 shares in the company, valued at $608,395.08. This trade represents a 12.92 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.93% of the stock is owned by company insiders.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.